Nasdaq: VRTXVertex Pharmaceuticals
Vertex Pharmaceuticals Q3 2026 Results: Net Income $654 Million on Revenue of $3.44 Billion
- US stocks
- Earnings
- Health Care

Vertex Pharmaceuticals (Nasdaq: VRTX) reported third quarter 2026 GAAP revenue of $3.44 billion and GAAP net income of $653.6 million, and it said on 2 Nov 2026 that the results cover the three months to 30 Sep 2026. GAAP diluted EPS was $2.56, and the company's adjusted diluted EPS, a company-defined measure that excludes items such as stock-based compensation, was $4.76.
Key highlights
- Revenue: $3.44 billion, up 11.8% YoY and 3.2% QoQ
- Net income (GAAP): $653.6 million, down 39.6% YoY
- Diluted EPS (GAAP): $2.56, down 39.0% YoY
- Adjusted diluted EPS (company-defined): $4.76
- Cash, cash equivalents and marketable securities: $9.8 billion at 30 Sep 2026
Summary
| Particulars | Q3 2026 | Q3 2025 | YoY | Q2 2026 | QoQ |
|---|---|---|---|---|---|
| Revenue | 3,440.8 | 3,076.4 | +11.8% | 3,333.9 | +3.2% |
| 712.9 | 1,186.2 | -39.9% | 1,246.9 | -42.8% | |
| Operating margin | 20.72% | 38.56% | -17.84 pp | 37.40% | -16.68 pp |
| 653.6 | 1,082.9 | -39.6% | 1,099.8 | -40.6% | |
| Net income margin | 19.00% | 35.20% | -16.20 pp | 32.99% | -13.99 pp |
| Diluted EPS ($) | 2.56 | 4.20 | -39.0% | 4.31 | -40.6% |
Figures are in $ million except EPS; YoY compares with Q3 2025 and QoQ with Q2 2026. Q3 2026 is the three months to 30 Sep 2026, from the company's release. Earlier quarters are checked against the company's SEC XBRL filings. GAAP; net income attributable to the company; diluted EPS. Changes and margins computed by Blacklitt.
GAAP operating margin was 20.7% in the quarter, against 38.6% a year earlier, a decline of 17.9 percentage points. GAAP net income margin was 19.0%, against 35.2% a year earlier. Revenue was up from the second quarter of 2026, while operating income and net income were lower than that quarter.
The company said the rise in operating costs reflected commercial investment to build out the renal franchise, the addition of Crinetics Pharmaceuticals, and investment in the JOURNAVX launch. It also said the quarter included approximately $500 million of compensation and transaction-related expenses tied to the Crinetics acquisition.
Adjusted figures exclude acquisition costs and other items
The company defines its non-GAAP measures to exclude items such as stock-based compensation, intangible asset amortization, changes in the fair value of strategic investments and contingent consideration, and acquisition-related costs. Acquisition-related costs were $502.0 million in the quarter's adjustments, and the company said they primarily relate to compensation on cash-settled Crinetics equity awards and transaction costs.
On the company's non-GAAP basis, net income was about $1.2 billion in both the third quarter of 2026 and the same quarter of 2025. Its non-GAAP effective tax rate was 18.0%, against 17.6% a year earlier, while the GAAP rate was 16.6% in both periods.
CF, CASGEVY and JOURNAVX revenue grew
Cystic fibrosis product revenues, net, were $3.27 billion in the quarter. ALYFTREK revenue was $705.8 million, against $247.0 million a year earlier, and TRIKAFTA/KAFTRIO revenue was $2.44 billion, against $2.65 billion.
CASGEVY revenue was $99.2 million, against $16.9 million a year earlier, and JOURNAVX revenue was $58.3 million, against $19.6 million. The company said PALSONIFY recorded $10.1 million of revenue in September 2026, after the Crinetics closing.
Full-year revenue guidance raised to $13.15 billion to $13.25 billion
The company now expects 2026 total revenue of $13.15 billion to $13.25 billion, up from its previous range of $13.1 billion to $13.2 billion. It expects combined GAAP R&D, acquired IPR&D and SG&A expenses of $7.15 billion to $7.2 billion, up from $6.3 billion to $6.45 billion, and combined non-GAAP expenses of about $6.0 billion, up from $5.65 billion to $5.75 billion.
The company also expects CASGEVY and JOURNAVX combined revenue of $500 million or more and PALSONIFY revenue of $40 million to $50 million. Its non-GAAP effective tax rate outlook is unchanged, and the previous range was 19.5% to 20.5%.
Inference
Diluted shares used in the per-share figures were 255.2 million, against 257.6 million a year earlier. The release does not give the amount of share repurchases in the quarter or a dividend declaration.
The next dated step is the FDA target action date of 30 Nov 2026 for povetacicept in IgAN, the company said.
Filed with the US SEC on . Reference: Original filing (SEC)
Disclaimer:
The information available on this article is provided for education and informational purposes only. It does not constitute or provide financial, investment or trading advice and should not be construed as an endorsement of any specific stock or financial strategy in any form or manner. We do not make any representations or warranties regarding the quality, reliability, or accuracy of the information provided. This website may contain links to third-party content. We are not responsible for the content or accuracy of these external sources and do not endorse or verify the information provided by third parties. We are not liable for any decisions made or actions taken based on the information provided on this website.
Figures are from the company's filings with the US Securities and Exchange Commission and are in US dollars. Investing in US stocks from India is subject to the Liberalised Remittance Scheme, currency risk and taxes in both countries.

